We are live on ! Find out more
CC

Checkpoint Capital Portfolio holdings

AUM $279M
1-Year Est. Return 45.74%
This Fund
S&P 500
This Quarter Est. Return
-4.92%
1 Year Est. Return
+45.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$182M
AUM Growth
-$14.2M
Cap. Flow
+$4.04M
Cap. Flow %
2.22%
Top 10 Hldgs %
98.23%
Holding
21
New
5
Increased
8
Reduced
1
Closed
7

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$14.2M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$9.95M
3
SEPN
Septerna Inc
SEPN
+$9.42M
4
RVMD icon
Revolution Medicines
RVMD
+$7.39M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$7.34M

Top Sells

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$18.5M
2
AXSM icon
Axsome Therapeutics
AXSM
+$14.8M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$10.6M
4
PLRX icon
Pliant Therapeutics
PLRX
+$7.05M
5
TRVI icon
Trevi Therapeutics
TRVI
+$4.47M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$54.1B
$68.1M 37.34%
115,000
+22,500
+24% +$14.2M
RYTM icon
2
Rhythm Pharmaceuticals
RYTM
$7.96B
$48.1M 26.37%
907,240
+179,258
+25% +$9.95M
RVMD icon
3
Revolution Medicines
RVMD
$44B
$13.9M 7.61%
392,011
+182,011
+87% +$7.39M
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
$12.4M 6.78%
172,902
+102,875
+147% +$5.01M
IRON icon
5
Disc Medicine
IRON
$2.97B
$12.1M 6.63%
243,311
+58,311
+32% +$3.24M
PTGX icon
6
Protagonist Therapeutics
PTGX
$9.44B
$8.47M 4.65%
+175,184
New +$7.34M
STOK icon
7
Stoke Therapeutics
STOK
$2.11B
$4.86M 2.67%
730,717
+425,330
+139% +$3.97M
SEPN
8
Septerna Inc
SEPN
$1.75B
$4.78M 2.62%
+824,878
New +$9.42M
KYMR icon
9
Kymera Therapeutics
KYMR
$8.94B
$3.74M 2.05%
136,605
+59,070
+76% +$2.15M
TCRX icon
10
TScan Therapeutics
TCRX
$52M
$2.78M 1.53%
2,017,650
+261,663
+15% +$566K
CDTX
11
DELISTED
Cidara Therapeutics
CDTX
$2.25M 1.23%
104,380
-92,569
-47% -$2.06M
CORT icon
12
Corcept Therapeutics
CORT
$12B
$571K 0.31%
+5,000
New +$304K
IMCR icon
13
Immunocore
IMCR
$1.73B
$267K 0.15%
+9,011
New +$270K
RAPT
14
DELISTED
RAPT Therapeutics
RAPT
$134K 0.07%
+13,729
New +$135K
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-1,004,790
Closed -$10.6M
AXSM icon
16
Axsome Therapeutics
AXSM
$10.9B
– –
-174,769
Closed -$14.8M
CYTK icon
17
Cytokinetics
CYTK
$10.4B
– –
-20,000
Closed -$941K
PHAT icon
18
Phathom Pharmaceuticals
PHAT
$692M
– –
-2,274,157
Closed -$18.5M
PLRX icon
19
Pliant Therapeutics
PLRX
$65M
– –
-535,494
Closed -$7.05M
TRVI icon
20
Trevi Therapeutics
TRVI
$2.64B
– –
-1,084,135
Closed -$4.47M
ATYR
21
aTyr Pharma
ATYR
$50.1M
– –
-432,561
Closed -$1.57M

Similar funds

CB
Centennial Bank Conway, Arkansas $279M AUM 20.11% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $278M AUM 14.53% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
BWG
Balanced Wealth Group Westlake, Ohio $279M AUM 17.49% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Checkpoint Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Checkpoint Capital held 21 positions worth $182M, down 7.2% from $196M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Checkpoint Capital's Q1 2025 filing shows 5 new, 8 increased, 1 reduced and 7 closed positions. Its largest new stake was Septerna Inc: 824,878 shares worth $4.78M. The largest sale was Phathom Pharmaceuticals, an estimated $18.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Checkpoint Capital's largest Q1 2025 buy was Septerna Inc: 824,878 shares worth $4.78M.
  • Checkpoint Capital added most to argenx in Q1 2025, an estimated $14.2M increase.
  • Checkpoint Capital's biggest Q1 2025 reduction was Cidara Therapeutics, cutting an estimated $2.06M.
  • Checkpoint Capital fully exited Phathom Pharmaceuticals in Q1 2025, selling an estimated $18.5M.
  • Checkpoint Capital's ten largest holdings make up 98% of its $182M portfolio in Q1 2025.
  • Checkpoint Capital opened 5 new positions and closed 7 in Q1 2025.
  • Checkpoint Capital's portfolio value fell 7.2% quarter-over-quarter to $182M.

Based on Checkpoint Capital's 13F filing for Q1 2025, filed 15 May 2025.